Kipferon, 10 pcs., vaginal and rectal suppositories
Rectally, intravaginally (before contact with the posterior vaginal vault and cervix). 1-2 supp. (depending on the severity of the disease), 2 times a day. The course of treatment is on average 10 days; in the presence of cervical erosion, use is continued until its epithelization. According to indications, the course of treatment can be repeated. Treatment should begin in the first days after the end of menstruation. Before insertion, it is recommended to remove mucus from the mucous membranes of the vagina and cervix.
Prescription regimens for the drug Kipferon®, suppositories
Chlamydial infections
Children - 1 supp. 1 time per day, for 10 days. In girls with erased clinical forms of chlamydial vulvovaginitis and without clinical manifestations of the inflammatory process of the uterus and its appendages, chlamydial urinary tract infection, respiratory chlamydia, treatment is carried out only against the background of vaginal and oral administration of eubiotics; in other cases, treatment of chlamydia in children with Kipferon® is combined with the prescription of antibiotics and eubiotics.
Adults - a daily dose of 1-2 million IU (2-4 supp.) in 2 doses, course of treatment - 10-14 days; Additionally, antibiotic therapy is carried out and eubiotics are prescribed vaginally and orally. If clinical signs of chlamydia or chlamydia infection persist after treatment, a repeat course of therapy with Kipferon® is administered.
For viral hepatitis B, C and A in children
Rectally. For children under 7 years of age, Kipferon® is prescribed in a single dose of 50,000 IU/kg body weight in 2 doses, but not more than 1 million IU/day (2 sup.); 8–11 years – 1.5 million IU/day (3 sup.); over 12 years old - 2 million IU/day (4 supp.). The duration of treatment for acute viral hepatitis is 14 days. For the first 7 days, the drug is used daily, then 2 times a week. With a protracted course of the disease, the course duration reaches 3–4 weeks.
For frequent inflammatory diseases of the respiratory tract, recurrent bronchitis (including obstructive syndrome), pneumonia in children
Rectally. In a daily dose of 1 million IU (2 supp.) in 2 divided doses daily for the first 5 days, then 2 times a week for 3 weeks. It can be used as monotherapy or in complex treatment against the background of basic antibacterial therapy.
For genital herpes
Adults: 1–2 million IU (2–4 supp.) for 10–14 days; a repeat course of treatment is possible; for children - a daily dose of 500,000 IU (1 supp.) in 1 dose, course of treatment - 10 days.
Antibiotic therapy for genital herpes is carried out only in the presence of a concomitant bacterial infection. In women and teenage girls, treatment with the drug is recommended to begin in the first days after the end of menstruation. Before vaginal insertion, it is advisable to remove mucus with a tampon from the mucous membranes of the vagina and cervix.
For intestinal infections in children
Rectally (after a cleansing enema or defecation). Children under 12 years old - in an average single dose of 50,000 IU/kg body weight, but not more than 1 million IU/day (2 supp.), over 12 years old - no more than 2 million IU (4 supp.). It is most advisable to use the drug in the first 3 days of the disease, i.e. during the acute period. The course of treatment for moderate viral diarrhea is 3–5 days; severe form - 7 days.
Kipferon® may be the only etiopathogenetic treatment (without antibacterial drugs) against the background of generally accepted basic therapy (oral rehydration, dosed therapeutic nutrition, and, if necessary, infusion therapy). In severe forms, it is advisable to include antibiotics in the complex of therapy.
In preparation for planned gynecological and other operations to prevent infectious complications
Rectally. Kipferon® is used in a daily dose of 1 million IU (2 sup.), in 2 doses, 3–5 days before and during surgery, as well as in the postoperative period. The course of treatment is 10–15 days. The interval between doses is 12 hours.
Kipferon
Kipferon supp vag and rect 200 mg+500000 IU x5, ATX code: G02CC (Anti-inflammatory drugs for intravaginal use)
Active substances
human normal immunoglobulin Ph.Eur. European Pharmacopoeia interferon alfa (interferon alfa) Rec.INN registered by WHO
Dosage form
Suppositories for vaginal and rectal administrationreg. No.: Р N000126/01 dated 02/28/11 - Indefinitely
Release form, packaging and composition of the drug Kipferon
Suppositories for vaginal or rectal administration 1 sup.
plasma protein (including IgM, IgA, IgG) 60 mg
interferon alpha 500 thousand IU, Clinical and pharmacological group: Immunomodulator. Combination of immunoglobulin with interferon Pharmacotherapeutic group: MIBP-cytokine
pharmachologic effect
The drug has immunostimulating, antiviral, antiherpetic effects.
As part of complex therapy, it is used to treat chlamydia.
Indications for the drug Kipferon
The drug is used in the treatment of acute respiratory diseases, inflammatory diseases of the oropharynx of bacterial and viral etiology, acute viral (rotavirus) and bacterial (salmonellosis, dysentery, coli infection) intestinal infections, intestinal dysbiosis of various origins in children, in the treatment of urogenital chlamydia in women, including manifestations of vaginal dysbacteriosis, vulvovaginitis, cervinitis of the cervix, and cervical erosion. The drug is also used against the background of generally accepted specific therapy.
ICD-10 codes
Dosage regimen
Suppositories containing immunoglobulin complex preparation (ICP) 0.2 g and human interferon alpha-2b, recombinant 500,000 IU as active substances, are used vaginally or rectally.
For acute respiratory diseases, inflammatory diseases of the oropharynx of bacterial and viral etiology, for viral (rotavirus) and bacterial (salmonella, dysentery, colo-infection) intestinal infections in children, intestinal bacteriosis of various origins, suppositories are prescribed depending on the age of the patients:
in the first year, 1 suppository per day rectally. (in 1 dose), from 1 to 3 years - 1 suppository twice a day, after 3 years - 1 suppository three times a day for 5-7 days.
In patients with tonsillitis with a pronounced purulent process, the course of treatment should be extended to 7-8 days.
Suppositories are used without specific therapy or simultaneously with it.
When treating urogenital chlamydia in women, suppositories are administered deeply intraginally (before contact with the posterior vaginal vault and cervix) 1-2 suppositories, depending on the severity of the disease, twice a day. The course of treatment is on average 10 days; in the presence of cervical erosion, the use of the drug is continued until its epithelization. According to indications, the course of treatment can be repeated. Treatment should begin in the first days after the end of menstruation. Before insertion, it is recommended to remove mucus from the mucous membranes of the vagina and cervix.
Contraindications for use
Individual intolerance to individual components, pregnancy and lactation.
Use during pregnancy and lactation Contraindicated during pregnancy and lactation.
Use in children Use is possible according to the dosage regimen.
Storage conditions for the drug Kipferon
Store the drug at a temperature of 2°C to 8°C, out of the reach of children.
Shelf life of the drug Kipferon Shelf life - 1 year 6 months. Do not use after the expiration date indicated on the package.
Terms of sale The drug is approved for use as an over-the-counter product.
Kipferon 200mg+500000me 10 pcs. vaginal and rectal suppositories Altfarm LLC/Binnopharm JSC
pharmachologic effect
MIBP-cytokine.
Composition and release form Kipferon 200 mg + 500000 me 10 pcs. vaginal and rectal suppositories Altfarm LLC/Binnopharm JSC
Suppositories - 1 sup.:
- Active ingredients: immunoglobulin complex preparation (ICP) - 0.2 g; interferon alpha-2b human, recombinant - 500,000 IU;
- Excipients: special-purpose confectionery fat “SolPro” for chocolate products and candies - 0.838 g; solid petroleum paraffin P-2 - 0.085 g; emulsifier “Solid” (T-2) - 0.085 g; sodium hydrogen phosphate dodecahydra - 0.055 mg; sodium dihydrogen phosphate dihydrate - 0.018 mg; sodium chloride - 0.110 mg; purified water - 0.012 g.
5 suppositories in a blister pack.
2 blister packs along with instructions for use in a cardboard pack.
Description of the dosage form
Suppositories are white, white with a yellowish tint or light beige in color, with a characteristic odor, cylindrical in shape with a pointed end, uniform in longitudinal section.
An air rod or funnel-shaped depression is allowed on the cut. Heterogeneity of color in the form of marbling is allowed.
Characteristic
A combination of recombinant human interferon alpha-2 and a complex immunobiological preparation (CIP) containing immunoglobulins of the main three classes G, A, M.
Directions for use and doses
Kipferon® is used rectally and vaginally. The drug is used in combination with generally accepted means of pathogenetic therapy of infectious diseases, as well as antibiotics according to indications.
The method and dosage regimen, as well as use in complex treatment, are determined by the doctor depending on the diagnosis, severity and severity of the disease.
Acute respiratory diseases, inflammatory diseases of the oropharynx of bacterial and viral etiology: suppositories are administered rectally (mainly after defecation) for children under 1 year old, one suppository per day, for children under 12 years old - 1 suppository twice a day, for adults and children over 12 years old 1 suppository three times a day.
The most effective and appropriate prescription of Kipferon® is in the acute period of the disease (preferably in the first 3 days). The duration of treatment is determined by the etiology, severity of the disease, the presence of associated complications, pathological conditions and is 5-7 days.
Acute viral (rotavirus) and bacterial (salmonellosis, dysentery, coli infection) intestinal infections, including with manifestations of intestinal dysbiosis of varying severity in children: suppositories are administered rectally (mainly after defecation) to children under 1 year old, one suppository per day, children under 12 years old - 1 suppository twice a day, adults and children over 12 years old - 1 suppository three times a day. The most effective and appropriate use of the drug is in the acute period of the disease (preferably in the first 3 days). The duration of treatment is determined by the etiology, severity of the disease, the presence of associated complications, pathological conditions and is 5-7 days.
Urogenital chlamydia in women (including pregnant women in the II-III trimesters of pregnancy), including manifestations of vaginal dysbiosis, vulvovaginitis, cervicitis of the uterus, cervical erosion: suppositories are administered deeply intravaginally (before contact with the posterior vaginal vault and cervix) 1-2 suppositories, depending on the severity of the disease, twice a day. The course of treatment averages 10 days; in the presence of cervical erosion, the use of the drug is continued until its epithelization. According to indications, the course of treatment can be repeated after one month. Treatment should begin in the first days after the end of menstruation. Before insertion, it is recommended to remove mucus from the mucous membranes of the vagina and cervix.
Pharmacodynamics
Suppositories Kipferon® is a complex dosage form containing human recombinant interferon-α2 and a complex immunoglobulin preparation (CIP).
Interferon-α2 is an activator of innate and acquired immunity, has pronounced antiviral activity, enhances protection against viral, chlamydial, mycoplasma and bacterial infections, has an immunomodulatory effect in the development of immunological reactions, promotes the growth and preservation of intestinal and vaginal flora.
The biological activity of interferon-α2 is realized through interaction with the receptor apparatus of immunocompetent and other cells, leading to increased expression of HLAI and HLAII molecules on the surface of all types of cells and regulation of cell cooperation, increased activity of natural killer cells, as well as imparting resistance to intact cells against their cytolytic action, proliferation of CD8 T cells.
Increases the production of interferon gamma by natural killer cells.
The complex immunoglobulin preparation KIP contains specific and nonspecific immunoglobulins of classes G, M, A. The combination of antiviral, antichlamydial, antibacterial and antitoxic antibodies belonging to various classes of immunoglobulins ensures agglutination, neutralization and precipitation of etiotropic pathogenic agents. At the site of application, it provides stabilization of interferon from the secretions of the mucous membranes, normalizes local immunity due to the supply of IgA and IgM with suppositories (replacement effect), and increases the activity of locally produced cytokines.
Indications for use Kipferon 200 mg + 500000 me 10 pcs. vaginal and rectal suppositories Altfarm LLC/Binnopharm JSC
The drug is used in the complex treatment of diseases accompanied by secondary immunodeficiency states:
- acute respiratory diseases, inflammatory diseases of the oropharynx of bacterial and viral etiology in children and adults;
- acute viral (rotavirus) and bacterial (salmonellosis, dysentery, coli infection) intestinal infections, including manifestations of intestinal dysbiosis of varying severity in children;
- urogenital chlamydia in women (including pregnant women in the II-III trimesters of pregnancy), including manifestations of vaginal dysbiosis, vulvovaginitis, uterine cervicitis, cervical erosion.
Contraindications
Individual intolerance to individual components, pregnancy first trimester, lactation period.
Application of Kipferon 200 mg + 500000 me 10 pcs. vaginal and rectal suppositories Altfarm LLC/Binnopharm JSC during pregnancy and breastfeeding
Application is possible according to the dosage regimen.
special instructions
Impact on the ability to drive vehicles and operate machinery
When used in recommended doses, the drug does not affect the behavior or functional parameters of the body, and also does not affect the ability to drive vehicles or machinery.
Overdose
There are no known cases of drug overdose.
Side effects Kipferon 200 mg + 500000 me 10 pcs. vaginal and rectal suppositories Altfarm LLC/Binnopharm JSC
Not registered.
Drug interactions
No negative effects on other drugs were noted.
